1. Scrip
  2. >>Rare Diseases

Reata Friedreich's Ataxia Drug Shows Late-Stage MOXIe

Reacquiring rights to omaveloxolone from AbbVie looks great business

 
• By Kevin Grogan

Analysts have been surprised by positive pivotal data for omaveloxolone, one of Reata's Nrf2 activators – along with bardoxolone – which the company is buying back from AbbVie for $330m.

Chart_Sketch
Reata stock is on the up on Friedreich’s ataxia data • Source: Shutterstock

Shares in Reata Pharmaceuticals Inc. have rocketed on positive data for omaveloxolone, one of the Nrf2 activators it reacquired the rights to less than a week ago from AbbVie Inc..

Reata has presented promising top-line data from the registrational second part of the 103-patient Phase II MOXIe trial of omaveloxolone for Friedreich’s ataxia (FA)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rare Diseases

More from Scrip

Executives On The Move: Altesa BioSciences Acquires Chief Medical Officer From GSK, Scholar Rock Gets A New CEO, And More

Recent moves in the industry include C-suite changes at Scholar Rock and Augustine Therapeutics, plus Contineum Therapeutics acquires chief medical officer from Gilead Sciences.

Dr Reddy’s Gears For Tariffs Scenario, To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Quick Listen: Scrip’s Five Must-Know Things

 
• By Ian Haydock

In this week's episode: industry makes its case to Trump; Sarepta slammed by double blow; Chinese firms build obesity pipeline; Swiss biopharma staying strong; and Merck & Co looks to immunology and ophthalmology.